Last reviewed · How we verify
Epocelin (CEFTIZOXIME)
Epocelin (CEFTIZOXIME) is a cephalosporin antibacterial drug, originally developed by Hoffmann-La Roche and currently owned by a generic manufacturer. It is a small molecule modality that was FDA approved in 1983 for various bacterial infections, including gonococcal infections and urinary tract infections. Epocelin is off-patent and has a generic manufacturer. Its half-life is 1.5 hours, but it has 0% bioavailability. It is used to treat a range of bacterial infections.
At a glance
| Generic name | CEFTIZOXIME |
|---|---|
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial peritonitis
- Bacterial septicemia
- Bacterial urinary infection
- Bacteroides Joint Infection
- Bacteroides Osteomyelitis
- Bacteroides Peritonitis
- Bacteroides Pneumonia
- E. Coli Pelvic Inflammatory Disease
- E. Coli Peritonitis
- Enterobacter Pneumonia
- Escherichia coli urinary tract infection
- Gonorrhea
- Gonorrhea of rectum
- H. Influenzae Meningitis
- Haemophilus influenzae pneumonia
Common side effects
- Rash
- Pruritus
- Fever
- Transient elevation in AST (SGOT)
- Transient elevation in ALT (SGPT)
- Transient elevation in alkaline phosphatase
- Transient eosinophilia
- Thrombocytosis
- Positive Coombs test
- Injection site burning
- Injection site cellulitis
- Injection site phlebitis
Serious adverse events
- Anaphylaxis
- Hemolytic anemia with fatal outcome
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Erythema multiforme
- Aplastic anemia
- Pancytopenia
- Agranulocytosis
- Pseudomembranous colitis
- Seizures
Key clinical trials
- Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |